Exchange Traded Concepts LLC Grows Holdings in Embecta Corp. $EMBC

Exchange Traded Concepts LLC grew its stake in shares of Embecta Corp. (NASDAQ:EMBC) by 519.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 124,429 shares of the company’s stock after buying an additional 104,334 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Embecta were worth $1,756,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Nuveen LLC purchased a new stake in Embecta during the first quarter valued at about $2,314,000. Raymond James Financial Inc. raised its holdings in shares of Embecta by 2.1% during the 1st quarter. Raymond James Financial Inc. now owns 326,156 shares of the company’s stock valued at $4,158,000 after buying an additional 6,640 shares in the last quarter. Comerica Bank lifted its position in Embecta by 65.7% in the 1st quarter. Comerica Bank now owns 50,641 shares of the company’s stock worth $646,000 after buying an additional 20,079 shares during the last quarter. State of Wyoming lifted its position in Embecta by 92.1% in the 1st quarter. State of Wyoming now owns 31,649 shares of the company’s stock worth $404,000 after buying an additional 15,170 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in Embecta by 38.3% in the first quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock worth $232,000 after buying an additional 5,036 shares in the last quarter. 93.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on EMBC. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a research note on Wednesday, October 8th. BTIG Research reiterated a “buy” rating on shares of Embecta in a research report on Tuesday, November 25th. Wall Street Zen raised shares of Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Zacks Research cut Embecta from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. One investment analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $18.50.

Embecta Stock Down 0.6%

Shares of Embecta stock opened at $12.01 on Friday. The company’s fifty day simple moving average is $13.06 and its two-hundred day simple moving average is $12.60. Embecta Corp. has a 12-month low of $9.20 and a 12-month high of $21.23. The firm has a market cap of $711.11 million, a PE ratio of 7.37 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Tuesday, November 25th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.46 by $0.04. The firm had revenue of $263.30 million during the quarter, compared to the consensus estimate of $265.66 million. Embecta had a net margin of 8.83% and a negative return on equity of 24.62%. The company’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.45 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts expect that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Friday, December 5th were given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 5.0%. The ex-dividend date was Friday, December 5th. Embecta’s dividend payout ratio (DPR) is currently 36.81%.

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.